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Abstract
The association between migraine and stroke is still a dilemma for neurologists. Migraine is associated with an
increased stroke risk and it is considered an independent risk factor for ischaemic stroke in a particular subgroup of
patients. The pathogenesis is still unknown even if several studies report some common biochemical mechanisms
between these two diseases. A classification of migraine-related stroke that encompasses the full spectrum of the
possible relationship between migraine and stroke includes three main entities: coexisting stroke and migraine,
stroke with clinical features of migraine, and migraine-induced stroke. The concept of migraine-induced stroke is well
represented by migrainous infarction and it is described in the revised classification of the International Headache Society
(IHS), representing the strongest demonstration of the relationship between ischaemic stroke and migraine. A
very interesting common condition in stroke and migraine is patent foramen ovale (PFO) which could play a
pathogenetic role in both disorders. The neuroradiological evidence of subclinical lesions most typical in the
white matter and in the posterior artery territories in patients with migraine, opens a new field of research. In
conclusion the association between migraine and stroke remains an open question. Solving the above mentioned
issues is fundamental to understand the epidemiologic, pathogenetic and clinical aspects of migraine-related stroke.
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Background
Migraine is a common, chronic, multifactorial neurovas-
cular disease, characterized by severe attacks of headache
and autonomic nervous system dysfunction. Migraine is
common among children and adolescents. Its prevalence
has a documented range from 0.5 to 13.6 % and increases
with age. Sex distribution is almost equal between ages of
7 and 11. During puberty, the balance shifts to a 3:1 ratio
between females and males, which extends into adulthood.
The two most common types of migraine in children are
migraine without aura (MO) and migraine with aura
(MA). Childhood periodic syndromes (cyclical vomiting,
abdominal migraine and benign paroxysmal vertigo of
childhood) frequently precede migraine and occur exclu-
sively in the pediatric population [1–4].
Migraine without aura, previously known as “common
migraine”, is the most frequent type of migraine, account-
ing for 60–80 % of all migrainous headaches. Children
experiencing migraine without aura have often prodromal
symptoms such as behavioral changes (e.g. irritability or
decrease in energy) and appearance abnormalities (e.g.
pallor, pigmented macules in the infraorbital region or
“dark rings under the eyes”). Migraine with aura is charac-
terized by occurrence of one or more fully reversible auras
before the onset of headache. Children may complain of
visual disturbances (visual auras) and hallucinations. Som-
atosensory aura, though uncommon, consists of perioral
paresthesias and/or numbness and tingling of hands or
feet (or both) [1–5].
Although migraine attacks may be acutely disabling,
they do not result in long-term brain consequences.
Against this assumption, new data have emerged
emphasizing migraine high prevalence among young
individuals with stroke, dysfunction of cerebral arter-
ies during migraine attacks and incidence of silent
infarct-like brain lesions in migraineurs. It suggests
thus that it might exists a comorbidity between mi-
graine and cerebral ischemia [6–8].* Correspondence: alberto.spalice@uniroma1.it
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Classification of migraine related stroke
One of the most relevant drawbacks in unrevealing the
complex relation between migraine and cerebral ischemia
is the lack of consistency while defining migraine-related
stroke.
Attempting a categorization, four major issues should
be considered:
 cerebral ischemia can occur during an attack of MA,
causing true migraine induced infarction;
 migraine and stroke share a common underlying
disorder increasing the risk for both diseases;
 migraine might cause stroke only as far as other risk
stroke factors are present interacting with the migraine
induced pathogenesis;
 stroke can mimic migraine [1–7].
The Table 1 presents an extended classification of
stroke associated with migraine or migraine-related
stroke.
Migraine-induced stroke: the migrainous infarction
According to the International Headache Society
(IHS) migraine classification, ‘migrainous infarction’ is
defined as a stroke occurring during a typical attack
of MA [1].
HIS criteria for migrainous infarction are:
 One or more migrainous aura symptoms not fully
reversible within 7 days and/or associated with
neuroimaging confirmation of ischemic infarction.
 Patient has previously fulfilled criteria for migraine
with neurologic aura.
 The present attack is typical of previous ones, but
neurologic deficits are not completely reversible
within 7 days and/or neuroimaging demonstrates
ischemic infarction in the relevant area.
 Other causes of infarction ruled out by appropriate
investigations.
According to large series, the incidence of migrainous
infarction varies between 0.5 and 1.5 % of all ischemic
strokes and 10 to 14 % of ischemic strokes in young
patients. Incidence of migraine-related infarction (per
100,000 persons per year) was estimated at 1.44 (95 %
CI, 0 to 3.07) from the Oxford shire Community Stroke
Project prospective registry [7–11].
Migraine and stroke share a common cause
Several vascular disorders can cause stroke and are
associated with a high risk of migraine, mostly MA.
Arteriovenous malformations (MAV) are the classical
cause of symptomatic migraine. A causal relationship
is supported by the side of the aura being contralateral
and the headache being ipsilateral to the MAV. Other
MA potentially associated conditions include lepto-
meningeal angiomatosis (Sturge Weber syndrome) and
hereditary haemorrhagic teleangectasia.
Ischemic stroke and migraine are also major clinical
features of some specific syndromes: cerebral autosomal-
dominant arteriopathy with subcortical infarcts and leu-
koencephalopathy (CADASIL), mitochondrial myopathy,
encephalopathy, lactic acidosis, and stroke-like episodes
(MELAS), cerebroretinal vasculopathy, and hereditary
endotheliopathy with retinopathy, nephropathy, and
stroke (HERNS). Coexistence of ischemic stroke and
migraine in a syndrome with a peculiar phenotype, a
confirmed inheritance and chronic alterations of the
wall of cerebral small-vessel arteries, highlights a
Table 1 Possible comorbidities between migraine and stroke
Type Definition
Migraine as a risk factor for stroke A clearly clinically defined stroke syndrome must occur remotely in time from a typical
attack of migraine
Migraine caused by stroke (symptomatic migraine) An acute vascular event in the central nervous system (ischemic or hemorrhagic stroke
or TIA) produces episodes of headache with the characteristics of migraine with or without
aura; to be coded as ICHD-II 6.1
Migraine as a caused of stroke (migrainous infarction) A documented infarct in a relevant area during the course of an attack of migraine with
aura, in a patient with a history of migraine with aura, with symptoms that are those of
the aura and in the absence of other possible causes at an extensive workup; to be coded
as ICHD-II 1.54
Migraine and stroke sharing a common cause A syndrome (usually of genetic origin) in which both migraine and stroke are major clinical
features (e.g. CADASIL [ICHID-II 6.7.1] or [ICHD-II] 6.7.2)
Migraine associated with subclinical stroke Evidence at brain neuroimaging of small areas compatible with brain ischemia in patients
without a history of any clinical symptom indicating a stroke syndrome
Migraine mimicking stroke (and vice versa: stroke
mimicking migraine)
Symptoms of migraine attacks (particularly aura without headache) and of stroke
(particularly TIAs) may overlap causing problems in the differential diagnosis
TIA transient ischemic attacks, ICHD-II International Classification of Headache Disorders, Second Edition, CADASIL Celebral Autosomal Dominant Arteriopathy with
subcortical Infarcts and Leucoencephalopathy; MELAS Mitochondrial Encephalopathy, Lactic Acidosis and Stroke like episodes
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common pathogenic mechanism between these two
conditions [1–6].
Ischaemic strokes and MA might also occur in many
general vascular disorders: cardiac disorders such as
patent foramen ovale and mitral valve prolapse, and
blood disorders such as essential thrombocythaemia,
thrombocytopenia, leukaemia, and systemic lupus erythe-
matosus. Co-morbidity can explain some cases others by
ischaemia-induced MA attacks and biochemical factors
such as serotonin changes in platelet disorders or some
immunological changes, especially antiphospholipid syn-
drome and systemic lupus erythematosus [1–12].
Stroke miming migraine
Transient ischemic attacks (TIA) and migraine auras are
both characterized by temporary focal neurological deficits;
starting from patient’s description, differential diagnosis be-
come clear when symptoms are typical. In migraine auras,
positive symptoms such as scintillations progress gradually
over several minutes and last about 30 min, after which
commonly occurs a severe headache. In transient ischemic
attacks, there is a focal deficit of sudden onset typically
lasting less than 15 min, without ensuing headache. MA
typically starts in childhood, whereas transient ischemic
attacks tend to occur in adulthood. Nevertheless, migraine
can present with TIA-like symptoms (eg, haemianopia
without headache) for the first time after 40 years of age.
Moreover, transient ischemic attacks, particularly basilar
transient ischemic attacks, can sometimes be associated
with headache. Mode of onset becomes a crucial distinctive
clinical feature [1–5]
Spontaneous cervical artery dissection (sCAD) is a
good example of a migraine mimic, especially because
patients with migraine are at increased risk of dissec-
tion. These symptomatic migraine attacks might be
more common than migraine-induced ischemic in-
sults. Cerebral infarction can thus present with mi-
graine attacks at onset, which should not be confused
with migrainous infarction. A stronger association was
observed among younger female, whose ischemic event
was located in the vertebrobasilar territory, with a per-
sonal history of migraine [11–14].
Coexisting ischemic stroke and migraine
Despite the apparent increased risk of stroke in migrai-
neurs, the high frequency of migraine in young adults
underlines its possible coexistence with ischemic stroke
without contributing to its development.
Being the etiology of these strokes probably multifac-
torial, identification and management of other estab-
lished risk factors should be pursued with particular
vigilance in all migraine sufferers [11–13].
Pathogenesis of migraine induced stroke
The mechanism of IS increased risk in migraine is un-
known and numerous hypotheses have been raised.
Hemodynamic factors
Migraine is considered a neurovascular disorder with
arterial constriction and posterior circulation decreased
blood flow as consequences of spreading wave of neur-
onal depression in the cerebral cortex. In this regard,
Cortical Spreading Depression (CSD) may induce cerebral
blood flow short-lived increases and tissue hyperoxia,
followed by deeper oligoemia and consequent increased
intraparenchymal vascular resistance. Thus, low flow in
major intracerebral vessels may be due to increased down-
stream resistance and not to major intracranial arterial
vasospasm. A low cerebral blood flow and neuronally me-
diated vasodilatation could then cause sluggish flow in
large intracerebral vessels during migraine auras. When
combined with coagulopathy predisposing factors, as de-
hydration hyperviscosity or intravascular thrombosis,
migraine-induced cerebral infarction may occur, even if
rarely [11–15].
Inflammatory factors
CSD is accompanied by vasodilatation of extrapaenchymal
vesels and release of neuronal inflammatory mediators.
Releasing of vasoactive peptides and nitic oxide, activation
of cytokines, and adhesion molecules upregulation also
predispose to intravascular thrombosis. This could explain
why migraine-induced stroke usually respects intracranial
arterial territories whereas aura involves more widespread
brain regions. Moreover, frequent aura due to CSD, could
induce cytotoxic cell damage and gliosis based on glutam-
ate release or excessive intracellular calcium accumula-
tion. Thus, a persistent neurologic deficit could be due to
selective neuronal necrosis.
Vasospasm was previously thought to be implied in
migraine aura, resulting from releasing of vasoconstrict-
ive molecules as endothelin and serotonin. In rare docu-
mented cases it was involved in migrainous infarction
[15–18].
Coagulation factors
Experimental data point toward activation of the throm-
botic cascade during a migraine attack. Indeed, platelets
and mast cells showed to release platelet activating fac-
tor (PAF), a potent inducer of platelet activation and ag-
gregation. PAF is also involved in the release of von
Willebrand factor, and indirectly in the activation of the
platelet IIb/IIIa receptor, crucial for binding fibrinogen
thus leading to primary hemostasis.
Increased plasma levels of these molecules have been
observed during the course of migraine attacks com-
pared with those of interictal phases [11–15]
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However, these mechanisms apply only for the so called
migrainous strokes, which, as defined by the IHS criteria,
are a rare event. This low incidence cannot explain then
the increased risk of stroke in migraine [11–17].
Migraine and patent foramen ovale
Patent foramen ovale (PFO), an interatrial communication
remnant of the fetal circulation, is due to a failure in the fu-
sion between septum primum and septum secundum. The
prevalence of PFO in healthy adult population is around
25 %. Several case–control studies observed that patent for-
amen ovale (PFO) is significantly more common in patients
who suffered MA than those without migraine. Right-to-
left cardiac shunt at rest through a PFO is more common
in migraineurs with aura than in non-migraineurs control
patients with PFO and patients with migraine tend to have
greater right-to-left shunts as compared to the non-
migrainous population. This suggests that interatrial
communication may play a role in the pathogenesis of
migraine. The mechanisms underlying this possible
association was postulated but never demonstrated.
Paradoxical embolism is suggested to be the causal link
between migraine and PFO, but data available are insuf-
ficient to substantiate the hypothesis that migraine fre-
quency (and, indirectly, ischemic stroke risk) is reduced
by PFO closure. A variable proportion of patients who
underwent PFO closure for non-migraine indications
however reported cessation or improvement of their
migraine attacks after the procedure. On the basis of
these findings, the possibility of a PFO–migraine– is-
chemic stroke triangular association remains a matter
of speculation [15–18].
Vascular factors
In the last years, some observations have suggested
migraine as a predisposing condition for sCAD, one of
the most common causes of stroke in young patients.
The mechanism by which migraine may affect the risk
of sCAD is unknown. A generalized vascular disorder is
hypothesized to be a predisposing condition for both
diseases. Recent observations in migraineurs of increased
activity of serum elastase, a metallopeptidase that degrades
specific elastin-type amino acid sequences, suggest a pos-
sible extracellular matrix degradation facilitating sCAD
occurrence. In line with previous observations of altered
common carotid artery distensibility in patients with
sCAD, it was recently reported that an endothelium-
dependent vasodilatation assessed in the brachial artery is
significantly impaired in these subjects. Similar vascular
changes were observed in migraine patients during inter-
ictal periods and replicated in a recent cross-sectional
study in migraineurs of recent onset, excluding the possi-
bility of a bias due to longstanding history of migraine and
repeated exposure to vasoconstrictor drugs. Finally, the
analysis of small families has shown that the structural ab-
normalities related to sCAD might be familial and follow
an autosomal-dominant pattern of inheritance. This sug-
gests that genetically determined alterations of the extra-
cellular matrix may play a crucial pathogenic role and that
candidate genes involved in endothelial and vessel wall
functions regulation might increase susceptibility to both
conditions [18, 19].
Endothelial factors
Inconsistent results have been found for the various
biologic or clinical markers of thrombotic risk studied
so far, such as platelet activation, factor V Leiden muta-
tion, von Willebrand factor, prothrombin factor 1.2,
platelet leukocyte aggregation, antiphospholipid antibodies,
and livedo reticularis. In contrast, there is mounting evi-
dence that migraine may be a risk factor for endothelial
dysfunction, a possible link to ischemic stroke and
heart disease.
Endothelial dysfunction is characterized by reduction
in bioavailability of vasodilators (such as nitric oxide),
increase in endothelial derived contracting factors, and
consequent impairment of vessels reactivity, including
the microvascular system. It represents the first step in
the development of atherothrombosis finally leading to
vascular events. It also comprises endothelial activation,
characterized by a procoagulant, proinflammatory and
proliferative state, which in turn predisposes to ischemia.
Endothelial dysfunction is mediated by increased oxida-
tive stress, an important promotor of the inflammatory
process, that might have a role in the pathogenesis of
migraine. Clinical investigation of markers of oxidative
stress in a migraine population during, after, and be-
tween migraine attacks yielded support for the associ-
ation. In fact, compared with migraine-free controls,
oxidative stress markers were found higher in migrai-
neurs, even during the interictal period, yielding sup-
port to the association [12–14].
Reduced endothelial repair capacity has emerged as
another possible connection between migraine and
vascular disease. Levels of endothelial progenitor cells,
measured using flow cytometry, were found lower in
migraineurs – particularly in those with aura – if com-
pared to healthy controls and to patients with tension-
type headache. Patients with migraine presented also
increased markers of senescence and decreased migratory
capacity of endothelial progenitor cells. Endothelial
progenitor cells derive from bone marrow, circulate in
peripheral blood, are capable of proliferation and dif-
ferentiation into endothelial cells and play a role in
neoangiogenesis after ischemia. Although it is not known
if the reduction of endothelial progenitor cells repre-
sents a primary alteration in migraine or the conse-
quence of migraine attacks itself, it is possible that
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their alteration mediates an increased vascular risk
[12–19].
Medications effects
Raised risk due to migraine treatments , particularly
vasoconstrictors, is supported by an increase in white
matter abnormalities and in mortality found in pa-
tients taking ergotamine, though recent studies found
no increase in severe vascular events treated with triptans.
Furthermore, drugs widely used in migraine, such as non-
steroidal inflammatory drugs, decrease the risk of cerebral
ischemic events [20].
Genetic influence on migraine-stroke relation
Over the past years, evidence from twins and family history
studies, although not entirely consistent, has supported the
notion that genetic predisposition plays a major role in the
occurrence of both migraine and ischemic stroke.
Monogenic forms of migraine
Even if many chromosomal regions were reported as pos-
sibly involved in migraine occurrence, mutations in three
genes for familial hemiplegic migraine (FHM) represent
the only established monogenic cause of migraine so far.
Familial hemiplegic migraine is a subtype of MA charac-
terized by an autosomal-dominant pattern of inheritance
and at least some degree of weakness (hemiparesis) during
the aura. In spite of these clinical markers, a broad vari-
ability rules: age at onset, frequency, duration and features
of attacks may differ from one patient to another, even
among affected members from a family carrying the same
mutation in the same gene. Less frequent features such as
cerebellar ataxia, occurring in some families, minor head
trauma acting as triggering factor and severe attacks with
impairment of consciousness have also been reported.
Moreover, even headache has been reported as the sole
clinical manifestation [2, 21]. Furthermore, the major-
ity of FHM patients experience attacks of typical MA
and MO. It seems then reasonable to assume that mi-
graine is composed by a spectrum of pathologic iden-
tities, starting from the common forms of migraine up
to FHM. The latter is thus a valid model to study gen-
etic factors of migraine in general as well as the rela-
tion between migraine and ischemic stroke. To date,
three different genes responsible for different subtypes
of FHM have been identified:
 FHM1 is caused by mutations in the CACNA1A
gene, located on chromosome 19p13, encoding the
pore-forming a1A subunit of Cav2.1 (P/Q type)
voltage-gated neuronal calcium channels;
 FHM2 is caused by mutations in the ATP1A2 gene,
located on chromosome 1q23, encoding the a2
subunit of sodium–potassium pump ATPases;
 FHM3 is caused by mutations in the SCN1A gene,
located on chromosome 2q24 encoding the a1 subunit
of the neuronal voltage-gated sodium channel
Nav1.1,crucial in action potentials generation and
propagation.
Overall, the common consequence of FHM1, FHM2,
and FHM3 mutations seems to be to increased levels of
glutamate and potassium in the synaptic cleft causing an
increased propensity to CSD. Whether this might also
increase the propensity to cerebral ischemia is unknown.
Similarly, the contribution of FHM genes in common
forms of migraine (MO and MA) remains unclear. A recent
study showed no linkage to the CACNA1A and ATP1A2
genes in families with apparently autosomal – dominant
mode of inheritance of MA, whereas a case – control study
investigating the role of the ATP1A2 gene in MA found no
evidence of association [11, 12].
Polygenic forms of migraine
New powerful technologies of gene analysis along with the
possibility to use informatics resources providing genome-
wide sequence and variant data has fostered an effective
and challenging approach to complex diseases. On the
basis of the results of such analysis, several specific genetic
variants have been implicated in migraine susceptibility
and it can be gathered from three main streams.
 The first group includes genes involved in
neurotransmitter-related pathway, such as genes
encoding for dopamine D2 receptor (DRD2), human
serotonin transporter (HSERT), catechol-O-
methyltransferase (COMT), and dopamine b-
hydroxylase (DBH).
 The second group includes genes involved in vascular
function, such as 5,10-methylenetetrahydrofolate
reductase (MTHFR), angiotensin I-converting enzyme
(ACE), and endothelin type A (ETA) receptor.
 The third group includes genes involved in
hormonal function, such as estrogen receptor 1
(ESR1), progesterone receptor (PGR) and androgen
receptor (AR).
Several genes candidate for migraine are also good
candidate for cerebral ischemia. Among them, in spite of
inconsistent results of some studies hypothesizing a link
between this marker and migraine, C677T polymorphism
of MTHFR gene looks particularly promising, due to its
probable independent effect on ischemic stroke risk. This
enzyme catalyzes the reduction of 5,10-MTHF to 5-
MTHF, the circulatory form of folate and carbon donor
for re-methylation of homocysteine (Hcy), a reactive thiol
amino acid, to methionine. It was found that with low
dietary folate, patients with migraine and MTHFR C677T
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variant homozygosis have a higher risk for elevated Hcy
(hyperhomocysteinemia or HHcy) levels. HHcy is defined
as Hcy level above 5–15_mol/L. Elevated Hcy levels were
reported in patients with MA. Animal studies suggest that
Hcy may increase migraine susceptibility by heightening
cerebral artery sensitivity. Hcy-related endothelial dys-
function seems involved in migraine beginning and main-
tenance of. Endothelial dysfunction may result from direct
damaging effect of Hcy on endothelium and altered oxida-
tive status. Hcy is indeed a risk factor for endothelial cell
injury, atherosclerotic vascular diseases, independent of
the long-recognized identified common risks. Autooxida-
tion of Hcy promotes the production of hydroxyl radicals,
thiolactone and known lipid peroxidation initiators with
creation of a prothrombotic environment. It is possible
that HHcy may result in temporary cerebral thrombosis
and/or altered blood flow, allowing less oxygen into the
brain and manifesting the common symptoms to MA and
ischemic stroke [12, 13].
Neuroimaging
Abnormalities of uncertain clinical significance are fre-
quent findings on brain MRI scans in patients with mi-
graine. The most common abnormality is white matter
lesions (WMLs), typically multiple, small, punctate hyper-
intensities, occurring in the deep or periventricular white
matter and often seen on T2-weighted or Fluid-Attenuated
Inversion Recovery (FLAIR) images. In a small minority of
cases, number, distribution, and location of WMLs may
lead to the diagnosis of an underlying disease of which mi-
graine may be but one symptomatic manifestation. Some
authors hypothesized that white-matter abnormalities are
due to ischaemic insults which leed to the suggestion that
migraine could be a progressive brain disorder [12].
Conclusion
The bidirectional relation between migraine and ischaemic
stroke, though poorly understood, has important practical
implications. To date, available data support the following
recommendations:
 Emphasis on identification and treatment of
modifiable vascular risk factors, such as smoking,
hypertension, diabetes, and hypercholesterolemia, is
warranted in migraineurs, especially those with MA.
 Because of the potential synergistic effect of several
migraine-specific drugs with vasoconstrictive action,
including triptans, and traditional predisposing
conditions in increasing the risk of ischemic
stroke, subjects with major cardiovascular risk
factors should be encouraged to adopt migraine
prophylactic strategies. This approach should be also
recommended to subjects with a personal history of
prior ischemic disease (cerebral and/or myocardial).
 There is no direct evidence that PFO closure is
effective for MA prophylaxis and, indirectly, for
primary prevention of stroke, and, this procedure
cannot thus be recommended for MA prophylaxis.
 Patients with migrainous stroke should undergo the
same diagnostic workup and receive the same
pharmacological treatment of any ischemic stroke in
the young, both during the acute phase and follow-up.
 Preventing disease progression in migraine has
already been added to traditional goals of relieving
pain and restoring patients’ ability to function. If
migraineurs brain lesions of have a significant clinical
correlation, preventing brain lesions accumulation
may become an additional goal of treatment. The
association of stroke with frequency of migraine
attacks suggests that migraine prophylaxis, especially
MA, may actually reduce migraine-related stroke risk.
It opens then issues of whether prophylactic drugs
decreasing such a risk (i.e., antihypertensives) might
be the best choice in these cases [17–20].
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